By Chelsea Naso ( January 22, 2015, 4:20 PM EST) -- Inotek Pharmaceuticals Corp., a venture capital-backed biotechnology company developing an eye drop treatment for glaucoma, set terms for its initial public offering and fine-tuned plans for a concurrent note offering Thursday, laying the groundwork to raise as much as $100 million....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.